| glaxosmithkline holdings limited | £2b | £63.4b | Mar 2020 | - | Open | Director |
| glaxosmithkline holdings limited | £2b | £63.4b | Mar 2020 | - | Open | Director |
| haleon uk holdings limited | - | £40.2b | Mar 2020 | - | Open | Director |
| glaxosmithkline mercury limited | - | £15.5b | Mar 2020 | - | Open | Director |
| smithkline beecham legacy h limited | - | £8.5b | Mar 2020 | - | Open | Director |
| wellcome limited | - | £6.2b | Mar 2020 | - | Open | Director |
| glaxochem (uk) unlimited | - | £4.7b | Mar 2020 | - | Open | Director |
| glaxosmithkline international limited | - | £3.9b | Mar 2020 | - | Open | Director |
| smithkline beecham limited | £140m | £2.5b | Mar 2020 | - | Open | Director |
| beecham group p l c | - | £1.8b | Mar 2020 | - | Open | Director |
| beecham group p l c | - | £1.8b | Mar 2020 | - | Open | Director |
| smith kline & french laboratories limited | - | £1b | Mar 2020 | - | Open | Director |
| smith kline & french laboratories limited | - | £1b | Mar 2020 | - | Open | Director |
| smithkline beecham (investments) limited | - | £915.4m | Mar 2020 | - | Open | Director |
| eskaylab limited | - | £698.1m | Mar 2020 | - | Open | Director |
| wellcome foundation limited(the) | - | £617.6m | Mar 2020 | - | Open | Director |
| burroughs wellcome international limited | - | £526.8m | Mar 2020 | - | Open | Director |
| glaxosmithkline ihc limited | - | £428.7m | Mar 2020 | - | Open | Director |
| smithkline beecham (h) limited | - | £229.8m | Mar 2020 | - | Open | Director |
| dealcyber limited | £14.6m | £173.5m | Mar 2020 | - | Open | Director |
| dealcyber limited | £14.6m | £173.5m | Mar 2020 | - | Open | Director |
| glaxosmithkline holdings (one) limited | - | £139.1m | Mar 2020 | - | Open | Director |
| smithkline beecham overseas limited | - | £105.2m | Mar 2020 | - | Open | Director |
| glaxo wellcome uk limited | £41.9m | £74.8m | Mar 2020 | - | Open | Director |
| stiefel laboratories (u.k.) ltd | - | £41.3m | Mar 2020 | - | Open | Director |
